Enlicitide: The First ORAL PCSK9 Inhibitor for Cholesterol

September 2026

Enlicitide (Lipfendra) is the first oral PCSK9 inhibitor to treat high cholesterol.

It joins the injectable PCSK9 inhibitors...alirocumab (Praluent), evolocumab (Repatha), inclisiran (Leqvio), and lerodalcibep (Lerochol).

All these meds help clear LDL cholesterol (LDL-C), or bad cholesterol, from the blood.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Immunizations Know What’s New With Flu Vaccines for 2026-2027
COVID-19 COVID-19 Prevention: Vaccines and Post-Exposure Prophylaxis
Med Safety Help Prevent Mishaps Involving Unusual Dosing Schedules
Cholesterol Enlicitide: The First ORAL PCSK9 Inhibitor for Cholesterol
Rumor vs Truth Substitute Confusion With Facts Around Generic Drugs
Pediatrics When Kids Have Type 2 Diabetes: A Treatment Guide
Supplements Help Patients Navigate the Peptide Craze
NatMed Spotlight Be Ready to Answer Questions About “Fibermaxxing”